Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1009120-03-9

Post Buying Request

1009120-03-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1009120-03-9 Usage

Description

(S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid is a chemical compound characterized by its molecular formula C11H17NO5. It is an amino acid derivative featuring a tetrahydropyran group, a type of cyclic ether, which endows it with unique structural features. (S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid serves as a versatile building block for the synthesis of a variety of pharmaceuticals and organic molecules, and it holds promise in the fields of medicinal chemistry and drug discovery.

Uses

Used in Pharmaceutical Synthesis:
(S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the formation of complex molecular structures that can exhibit therapeutic properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid is utilized as a structural component in the design and development of new drugs, potentially leading to innovative treatments for various diseases.
Used in Drug Discovery:
(S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid is employed in drug discovery processes to explore its potential as a precursor to new bioactive molecules, which may offer novel mechanisms of action or improved pharmacokinetic profiles.
While the specific applications and properties of (S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid are still under investigation, its unique structure suggests a broad range of possibilities across different industries, particularly in healthcare and pharmaceutical development. Further research is essential to fully realize its potential and optimize its use in these areas.

Check Digit Verification of cas no

The CAS Registry Mumber 1009120-03-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,9,1,2 and 0 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1009120-03:
(9*1)+(8*0)+(7*0)+(6*9)+(5*1)+(4*2)+(3*0)+(2*0)+(1*3)=79
79 % 10 = 9
So 1009120-03-9 is a valid CAS Registry Number.

1009120-03-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017

1.Identification

1.1 GHS Product identifier

Product name (S)-2-((methoxycarbonyl)amino)-2-(tetrahydro-2H-pyran-4-yl)acetic acid

1.2 Other means of identification

Product number -
Other names (S)-2-(methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)acetic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1009120-03-9 SDS

1009120-03-9Relevant articles and documents

HEPATITIS C VIRUS INHIBITORS

-

Paragraph 0570-0571, (2017/07/05)

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

-

Page/Page column 64-66, (2013/03/28)

The present invention relates to novel Silyl-Containing Heterocyclic Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, D, E, F and L are as defined herein. The present invention also relates to compositions comprising at least one Silyl-Containing Heterocyclic Compound, and methods of using the Silyl-Containing Heterocyclic Compounds for treating or preventing HCV infection in a patient.

HEPATITIS C VIRUS INHIBITORS

-

Paragraph 0293; 0294, (2013/11/06)

The invention provides compounds of formulas (I) or (II): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1009120-03-9